The health care company binx health said that their proprietary Chlamydia and Gonorrhea (CT/NG) test has received European CE Mark approval. The new multiplex test works with the binx io platform, delivering a laboratory-quality result in about 30 minutes, creating a new model for “test-and-treat” care for two of the most prevalent Sexually Transmitted Infections (STIs) globally.
Gonorrhea and chlamydia represents two of the most prevalent acquired STIs acquired worldwide. If left untreated, gonorrhoea can cause serious and permanent problems from pelvic inflammatory disease, infertility, risks of ectopic pregnancy in women to epididymo-orchitis and problems with the prostate gland bruising the urethra and making urination painful and difficult in men. Gonorrhoea also affects the blood and the joints and exposes one to HIV that causes AIDS. Chlamydia is a sexually transmitted infection that often occurs together with gonorrhoea.
Diagnosis of gonorrhoea is a very long-drawn process. The doctor will run a series of tests from taking samples for laboratory analysis of urine, fluid from the urethra in men, cervix in women, swabs from the throat and the anus to check if the infection is present there as well.
The waiting period from first visit to treatment may allow spread infection in the patients.
The company states that the binx io platform enables easier for any non-laboratory-trained users to run the test with the same accuracy as a central lab test, making it ideal for use in a variety of approved medical and consumer settings.
“Achieving a 30-minute diagnostic turnaround time for two of the most common STIs is a major public health breakthrough,” explains Howard Heller, MD MPH, binx health’s Chief Medical Officer in a press release.
“Rapid results equal rapid, appropriate treatment. This new panel enables a path to not just same day, but same visit testing and treatment, eliminating an immense barrier to care and cure.”